Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
ONCYOncolytics Biotech (ONCY) Prnewswire·2024-10-04 19:00

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registrationenabling studies SAN DIEGO and CALGARY, AB, Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to pr ...